'CROs on the move': inVentiv's new UK site; Novum in North Dakota

The contract research services organization has consolidated three sites situated in Greater London into one single three-storey building in Maidenhead, just outside the capital in a move the firm says will improve integration and knowledge-sharing across the clinical, commercial and consulting businesses.

“The consolidation was designed to accommodate our expanding team and facilitate the convergence of services by aligning our Clinical, Commercial and Consulting segments,”​ Steve Mitchell, Senior Director of Clinical Data Management, told Outsourcing-Pharma.com. “It positions us for anticipated growth.”​

He continued: “We provide virtually every service a biopharmaceutical company needs from advice and execution of clinical development of compounds in early stage through to Late Stage clinical trials, launch and commercialization to the very end of the product lifecycle.​

“Over the past two years, we’ve been putting these services together in utterly unique ways to provide innovative solutions to our clients’ specific business needs.  Consolidating our team members with diverse expertise under one roof facilitates this strategic approach to biopharmaceutical services.”  ​

Furthermore, he added, “The Maidenhead office is seen under our global strategic plan as the corporate hub for inVentiv Health Europe and the seat for all three of our segments, Clinical, Commercial and Consulting.”​

On top of that, “it’s also more cost efficient and a very nice place to work,”​ he said.

The new site will accommodate 180 employees and the company plans to add more over the next few months.

Novum Enters Fargo​

Across the Atlantic and in other CRO news, Novum Pharmaceutical Research Services has opened a new clinical facility in Fargo, North Dakota.

The CRO offers Phase I-IV clinical trials and the new site will add early phase research services as well as strengthen Novum’s network and accommodate future growth.

“Fargo represents the perfect opportunity for Novum and our clients, providing us with added capacity, committed study participants, and a strong local team of clinical and scientific talent,”​ CEO Christopher Chamberlain said.